[HTML][HTML] 治疗前NLR 对于接受卡瑞利珠单抗联合靶向治疗的肝癌患者的预后预测价值
王胜亮， 赵延荣， 马天兴， 郭源 - Advances in Clinical Medicine, 2024 - hanspub.org
目的: 探讨治疗前中性粒细胞与淋巴细胞比值(Neutrophil-to-Lymphocyte Ratio, NLR)
对接受卡瑞利珠单抗联合靶向治疗的中晚期肝细胞癌(Hepatocellular Carcinoma, HCC) …
对接受卡瑞利珠单抗联合靶向治疗的中晚期肝细胞癌(Hepatocellular Carcinoma, HCC) …
NLR 对TACE 联合仑伐替尼及免疫治疗的中晚期肝癌患者预后的预测价值
申雪晗， 周江敏， 张志伟， 陈孝平 - 肝胆胰外科杂志, 2023 - gdy.qk.wmu.edu.cn
目的探讨中性粒细胞/淋巴细胞比值(NLR) 对接受肝动脉化疗栓塞(TACE) 联合仑伐替尼及免疫
治疗的中晚期肝癌患者预后的预测价值. 方法回顾性分析2019 年1 月至2021 年10 …
治疗的中晚期肝癌患者预后的预测价值. 方法回顾性分析2019 年1 月至2021 年10 …
卡瑞利珠单抗联合安罗替尼治疗中晚期肝癌的疗效和安全性
蔡宇， 赵长海， 罗利琼 - 循证医学, 2022 - jebm.cn
目的回顾性分析既往接受过系统治疗后病情进展的中晚期(BLCL 分期B/C)
肝癌患者使用卡瑞利珠单抗联合安罗替尼治疗的疗效和安全性. 方法收集2019 年10 月至2021 …
肝癌患者使用卡瑞利珠单抗联合安罗替尼治疗的疗效和安全性. 方法收集2019 年10 月至2021 …
Serum neutrophil/lymphocyte ratio as a potential predictor of treatment response for immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma.
J He, Z Mo, Q Mai, X Chen - 2021 - ascopubs.org
e16156 Background: Neutrophil to lymphocyte ratio (NLR) has been shown to associate
with tumor progression. The present study was to investigate the role of NLR on predicting …
with tumor progression. The present study was to investigate the role of NLR on predicting …
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with …
S Matoya, T Suzuki, K Matsuura, Y Suzuki… - Hepatology …, 2023 - Wiley Online Library
Abstract Aim Atezolizumab plus bevacizumab (Atez/Bev) therapy is expected to have good
therapeutic efficacy for patients with advanced hepatocellular carcinoma (HCC). However …
therapeutic efficacy for patients with advanced hepatocellular carcinoma (HCC). However …
Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma
Y Kaneko, M Kaneshiro, H Watanabe - Nihon Shokakibyo Gakkai …, 2023 - europepmc.org
This study aimed to investigate the significance of neutrophil-to-lymphocyte ratio (NLR) as a
prognostic predictor by reporting 21 patients with unresectable hepatocellular carcinoma …
prognostic predictor by reporting 21 patients with unresectable hepatocellular carcinoma …
[引用][C] 167P Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with …
X Peng, W Zhang, C Gong, T Liu… - Annals of …, 2023 - annalsofoncology.org
Background The study aimed to evaluate baseline and dynamic changes of serum
neutrophil-to-lymphocyte ratio (NLR) level as biomarkers of response to anti-PD-1/PD-L1 …
neutrophil-to-lymphocyte ratio (NLR) level as biomarkers of response to anti-PD-1/PD-L1 …
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular …
H Ochi, M Kurosaki, K Joko, T Mashiba… - Hepatology …, 2023 - Wiley Online Library
Aim We investigated pretreatment neutrophil‐to‐lymphocyte ratio (NLR) for predicting
survival outcomes of atezolizumab plus bevacizumab therapy for hepatocellular carcinoma …
survival outcomes of atezolizumab plus bevacizumab therapy for hepatocellular carcinoma …
Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma
Background: Combination therapy with anti-programmed death-ligand 1 monoclonal
antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab …
antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab …
Influence of neutrophil-lymphocyte ratio on prognosis of liver cancer: A meta-analysis
G ChiDan, Z LiXin, Q Gang, Z YuShun, L JingDong - 临床肝胆病杂志, 2017 - lcgdbzz.org
Objective To investigate the association between neutrophil-lymphocyte ratio (NLR) and
prognosis of liver cancer. Methods Pub Med, Embase and Cochrane Library, CBM, VIP …
prognosis of liver cancer. Methods Pub Med, Embase and Cochrane Library, CBM, VIP …